When Is FDA Form 3331A Required? (w/Examples) + FAQs

FDA Form 3331A is required when a pharmaceutical manufacturer holding an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) receives information about significant quality problems with a distributed drug product. The form must be submitted within three working days of receiving such information.

Under 21 CFR 314.81(b)(1), Field Alert Reports (FARs) serve as an early warning system that helps FDA protect patient health by rapidly identifying quality defects in distributed medications. In FY2024, FDA received 3,515 Field Alert Reports—a 7.5% decrease from the prior year—yet the agency significantly increased for-cause inspections by nearly 250% in 2025, with sites now facing a 33.5% chance of Official Action Indicated classification following such inspections.

Here’s what you’ll learn:

📋 The four specific triggers that legally require you to file FDA Form 3331A and the exact three-day deadline calculation

⚠️ Common filing mistakes that result in Form FDA 483 observations and potential warning letters

📝 Step-by-step instructions for completing every field on Form 3331A correctly

🏭 Real-world scenarios showing when FARs are required versus optional

❓ Critical FAQs answered including OOS results, media fill failures, and recall obligations

What Is FDA Form 3331A and Why Does It Exist?

FDA Form 3331A is the standardized form used to submit Field Alert Reports electronically to the FDA. It replaced the older Form FDA 3331 in 2017 after a four-year pilot project demonstrated that electronic XML-enabled submissions improved the speed and efficiency of reporting on product quality issues.

The FAR system originated from regulatory requirements first published in 1985 implementing Section 505(k) of the Federal Food, Drug, and Cosmetic Act. These requirements create an early warning mechanism that allows FDA to take rapid action—including potential product recalls—when a drug quality or safety issue poses a public health risk.

Form 3331A uses XML technology to automatically route submissions simultaneously to both CDER (Center for Drug Evaluation and Research) and the appropriate FDA district office. This eliminates the previous need to fax or scan documents, creating a streamlined compliance process.

The Four Legal Triggers That Require Filing Form 3331A

The regulation at 21 CFR 314.81(b)(1) specifies four categories of information that mandate FAR submission:

The phrase “significant” is product-specific and requires evaluation of the potential impact on the drug product’s identity, strength, purity, stability, and efficacy—along with how that change could affect patients using the medication.

Who Must Submit FDA Form 3331A?

The NDA or ANDA applicant bears legal responsibility for submitting the FAR—not contract manufacturers, testing laboratories, or distributors. However, this responsibility cannot be delegated away simply because manufacturing or testing activities are outsourced.

According to FDA’s guidance on Contract Manufacturing Arrangements, quality agreements with contracted entities must establish procedures ensuring those entities notify the applicant of reportable information in a timely manner. The three-day clock starts when anyone in the supply chain receives qualifying information—not when the applicant headquarters learns about it.

Products Subject to FAR Requirements:

• All NDA-approved drug products
• All ANDA-approved generic drugs
• Drug-device combination products (under 21 CFR Part 4, Subpart B)
• Positron emission tomography (PET) drugs
• Designated medical gases (under Section 576(a)(3) of the FD&C Act)
• Products distributed outside the United States under an NDA/ANDA

Calculating the Three Working Day Deadline

The term “working days” means Monday through Friday, excluding U.S. Federal holidays. The day information is received is considered Day 0, and the FAR must be submitted by close of business on Day 3.

Deadline Calculation Example:

This timeline applies regardless of where the qualifying information is identified. If a contract laboratory in India discovers a problem on their Friday, Day 0 is that Friday (using U.S. calendar), and the three-day countdown follows U.S. working days.

The regulation requires submission within the timeframe even if the investigation is incomplete. Initial FARs should contain whatever information is available at the time of submission.

Three Real-World Scenarios Requiring FDA Form 3331A

Scenario 1: Stability OOS Result on Distributed Batch

Situation: During routine 24-month stability testing, an analyst discovers the dissolution rate for a distributed batch of metformin tablets has dropped to 72%—below the 75% specification limit.

Key nuance: If the OOS result can be scientifically invalidated within 3 working days—for example, by confirming an analytical laboratory error—no FAR is required. However, the investigation must be thoroughly documented per 21 CFR 211.192.

Scenario 2: Consumer Complaint of Foreign Material

Situation: A pharmacy reports finding small black particles in three bottles of liquid acetaminophen suspension from the same lot currently in distribution.

Key nuance: FDA expects firms to submit FARs for recurring technical defects discovered through complaints even when there is no evidence of the issue in site production records or retained samples. The defect may have occurred during distribution.

Scenario 3: Media Fill Failure at Sterile Manufacturing Facility

Situation: A routine aseptic process simulation (media fill) at a sterile injectable manufacturing facility shows microbial growth in 2 of 5,000 units tested.

Key nuance: A media fill failure alone does not automatically require a FAR. However, the mandatory investigation will often reveal information about distributed products that does meet FAR criteria. The FAR is then required within 3 working days of that discovery.

How to Complete FDA Form 3331A: Field-by-Field Instructions

The form is available as a fillable PDF on FDA’s Field Alert Reports webpage. Below is guidance for each section:

Box 1: Firm Name and Address Where Problem Occurred

Enter the name and complete address of the facility where the problem originated. For foreign facilities, include the full international address.

Nuance: If the problem involves an API or component supplier (not the finished product manufacturer), list the supplier’s facility information here. Then include the finished product manufacturer’s information in Box 14 (Remarks).

Box 2: DUNS/FEI Number

Enter the Data Universal Numbering System (DUNS) number and/or the Facility Establishment Identifier (FEI) number. At least one is recommended. If unknown, enter “N/A” or check the N/A box.

Box 3: NDA/ANDA Number

Select NDA or ANDA and enter the application number. For CBER-regulated products, include the prefix “BN” (for NDA) or “BA” (for ANDA) before the numeric portion. This field is limited to eight characters.

Critical rule: If multiple applications are affected by the same problem, you must submit a separate Form 3331A for each application—even if the problem occurs at a single facility.

Box 4: NDC Number

Enter the National Drug Code using formats 4-4-2, 5-4-1, or 5-3-2. Separate multiple NDC numbers with semicolons.

Box 5: Generic Name of Drug Product

Enter the established (generic) name of the drug product as it appears in the approved application.

Box 6: Trade/Brand Name

Enter the brand or proprietary name if applicable.

Box 7a and 7b: Dosage Form, Strength, and Package Size

Enter the dosage form (tablet, capsule, injection, etc.) and the strength with appropriate units as indicated in approved labeling.

Box 8: Lot Number, Expiration Date, Batch Size, Consumer Complaints

Enter each value separated by commas. For multiple lots, separate each complete set with semicolons.

Example: “LOT123, 12/2026, 500000, 3; LOT456, 03/2027, 500000, 0”

Box 9: Date When Notified About Problem

Enter the date the applicant first received information meeting FAR criteria—not when the problem was confirmed. This is Day 0 for the three-day deadline.

Box 10: How Was Problem Discovered?

Select or describe how the issue came to light (complaint, stability testing, in-process testing, etc.).

Box 11: State Problem(s)

Describe the quality issue using ICH Q10 terminology when possible. List the most important terms first.

Box 12: Quality Issue/Defect (Structured)

Provide additional structured information about the defect in narrative format.

Box 13: Reported Quality Issue/Defect

Include complete narrative description of the problem being reported.

Box 14: Describe Root Cause(s)

Provide the root cause if determined. If not yet identified, provide a brief summary of investigations conducted or ongoing.

Box 15: Describe Corrective Actions

Document all corrective actions taken to date to prevent recurrence.

Box 16: Remarks

Provide additional pertinent information. For initial FARs, indicate the estimated date for follow-up or final report submission. For follow-up or final FARs, reference the original submission date.

Submitting the Completed Form

Once all fields are completed:

1. Save the form to your computer before clicking “Submit by Email”
2. Use File/Print to create a read-only PDF version
3. Click the “Submit by Email” button
4. The system will automatically attach the XML data and create a standardized subject line
5. Attach the read-only PDF manually to the email
6. Send to the FDA district office selected on page ii of the form

District Office Selection:

• Domestic facility problem: Select the district office for that facility’s geographic location
• Foreign facility problem: Select the district office where your U.S. agent or authorized representative resides
• Unknown location: Select the district where the problem most likely occurred; list additional suspected sites in Box 16

The form no longer requires a signature from an authorized representative.

Initial, Follow-Up, and Final FARs Explained

Although follow-up and final FARs are not legally mandated, FDA strongly encourages their submission. The agency uses this information to assess public health risk, determine the adequacy of corrective actions, and decide whether surveillance inspections are needed.

When to submit a Follow-Up FAR:

• Significant findings during investigation
• Additional lots identified within scope
• New facilities implicated
• Correction of previously submitted incorrect information

When to submit a Final FAR:

• Root cause identified
• CAPA implemented
• Investigation closed

Mistakes to Avoid When Filing FDA Form 3331A

Based on FDA’s common reporting errors and warning letter citations, avoid these mistakes:

Do’s and Don’ts for FDA Form 3331A Compliance

Do’s

✅ Do establish written procedures with contract manufacturers and testing laboratories specifying how they must notify you of reportable events—and within what timeframe. Quality agreements should explicitly address FAR notification requirements.

✅ Do submit the initial FAR even with incomplete information. FDA expects whatever information is available within 3 working days. Follow-up reports can provide additional details as the investigation progresses.

✅ Do use the manufacturer control number consistently across initial, follow-up, and final FARs for the same problem. This allows FDA to link related submissions.

✅ Do carbon copy the district office where your headquarters (or U.S. agent) is located if different from the district receiving the primary submission. This ensures comprehensive agency awareness.

✅ Do document your “significance” determinations. When concluding that a change or deterioration is not significant (and therefore doesn’t require a FAR), document the evaluation, factors considered, and rationale per 21 CFR 211.192.

Don’ts

❌ Don’t wait for OOS invalidation beyond 3 working days. If an OOS result cannot be scientifically invalidated within the deadline, a FAR is required. You can submit a follow-up if the result is later invalidated.

❌ Don’t assume foreign distribution exempts you. Products marketed under an approved NDA or ANDA—whether distributed domestically or abroad—are subject to FAR requirements.

❌ Don’t rely solely on retained sample analysis. When complaints suggest quality issues, the absence of problems in retained samples doesn’t eliminate FAR obligations—defects may occur during distribution.

❌ Don’t use the old Form FDA 3331. The original form is obsolete. Only Form FDA 3331a should be used for submissions.

❌ Don’t submit FARs through the Electronic Submissions Gateway (ESG) yet. While FDA is working on eCTD integration, FARs are currently submitted via email using Form 3331a’s automated features.

Consequences of Failing to Submit Required FARs

Failure to submit a required FAR violates both 21 CFR 314.81(b)(1) and Section 505(k) of the FD&C Act. Violating Section 505(k) is a prohibited act under Section 301(e), carrying potential consequences including:

A 2024 warning letter observation specifically cited: “The firm did not notify the FDA of a labeling error that could result in product mix-up, as required under 21 CFR 314.81(b)(1).”

Relationship Between FARs and Product Recalls

FARs and recalls serve different purposes but often overlap:

A recall does not eliminate the FAR requirement. If the information leading to a recall meets FAR criteria, both submissions are required. FDA recommends submitting a follow-up or final FAR at the time of recall notification to link the actions.

Conversely, submitting a FAR does not automatically trigger a recall. The FAR alerts FDA to a potential problem; the need for recall depends on the health hazard evaluation conducted by the firm and assessed by FDA.

Special Situations and Nuances

Products Not Yet Distributed

FARs are only required for distributed drug products. If an OOS result or contamination is discovered before commercial distribution, no FAR is needed. However, if the investigation reveals issues affecting previously distributed batches, a FAR becomes mandatory.

Multiple Complaints About Same Batch

If you receive additional complaints while investigating an open FAR for the same problem, same NDA/ANDA, and same batch—do not submit a separate FAR for each complaint. Instead, provide a cumulative list of related complaints in your final FAR.

Complaints About Products from Different Batches

If a new complaint involves a different batch than the one in your open FAR, evaluate whether it represents the same underlying problem. If related, update the existing FAR. If unrelated, a new initial FAR may be required.

Biological Products Under BLAs

Products approved under Biologics License Applications (BLAs) follow different reporting requirements. Biological Product Deviation Reports (BPDRs) under 21 CFR 600.14 must be submitted within 45 calendar days—significantly longer than the 3-day FAR deadline. BLA holders use Form FDA 3486 rather than Form 3331A.

Drug-Device Combination Products

For combination products approved under an NDA or ANDA, FAR requirements apply to the drug constituent part. The PMSR rule at 21 CFR Part 4 coordinates reporting across constituent parts to avoid duplication while ensuring complete information reaches FDA.

FAQs

Does every consumer complaint require a FAR?
No. Consumer complaints must be evaluated within 3 working days to determine if the information meets FAR criteria under 21 CFR 314.81(b)(1). Only complaints indicating product mix-ups, contamination, significant deterioration, or specification failures require FAR submission.

Can I submit a FAR after the 3-day deadline has passed?
Yes. Late submission still violates the regulation, but you must still submit the required FAR. FDA may cite the delay as a separate compliance observation, but failure to submit at all compounds the violation.

Is FDA Form 3331A required for OTC monograph products?
No. OTC monograph products are not approved under NDAs or ANDAs and therefore are not subject to FAR requirements under 21 CFR 314.81. Different reporting mechanisms apply.

Do I need to submit two copies of an electronic FAR?
No. Electronic submission of Form FDA 3331a as instructed in the form instructions fully satisfies the regulatory requirement. Paper copies are unnecessary when submitting electronically.

Can a follow-up FAR cover multiple NDAs/ANDAs?
Yes. While initial FARs must be submitted separately for each application, a single comprehensive investigation can generate one follow-up or final FAR that references all affected products, NDA/ANDA numbers, and discovery dates.

Must I submit a FAR if I identify and correct the root cause within 3 days?
Yes. The regulation requires FAR submission regardless of whether the investigation identifies a root cause or implements corrective action. The FAR should detail the identified root cause and completed or ongoing corrections.

Are FARs required for investigational drugs under INDs?
No. FAR requirements apply only to products approved under NDAs or ANDAs. Investigational products have separate safety reporting requirements under 21 CFR 312.

Does submitting a FAR automatically trigger FDA inspection?
No. FARs inform FDA of potential quality issues but do not automatically result in inspection. However, FDA uses FAR data in its Site Selection Model to prioritize surveillance inspections, so patterns of FARs may increase inspection likelihood.

Is a signature required on Form FDA 3331A?
No. The current version of Form FDA 3331a eliminated the signature requirement, simplifying the submission process by removing the need to print, sign, and scan the form.

Can I use Form 3331A for products regulated by CBER?
Yes. Form FDA 3331a can be used to submit FARs for both CDER and CBER-regulated drug products approved under an NDA or ANDA. For biologics under BLAs, use Form FDA 3486 for BPDRs instead.